Treatment of bleeding with low half-life fibrinogen
US9212215B2 · kind B2 · utility
1Cited by
4References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 20, 2013 |
| Grant date | Dec 15, 2015 |
| Priority date | — |
| Expiry date | Feb 20, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/75
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A fibrinogen with reduced half-life and low sialic acid content as a result of recombinant expression or enzymatic and chemical removal. The fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.